Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 21,726 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $61.26, for a total transaction of $1,330,934.76. Following the completion of the sale, the chief financial officer now directly owns 55,639 shares in the company, valued at $3,408,445.14. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jason Ryan also recently made the following trade(s):

  • On Thursday, November 2nd, Jason Ryan sold 9,731 shares of Foundation Medicine stock. The shares were sold at an average price of $50.00, for a total transaction of $486,550.00.
  • On Thursday, October 12th, Jason Ryan sold 1,152 shares of Foundation Medicine stock. The stock was sold at an average price of $45.05, for a total transaction of $51,897.60.
  • On Monday, October 2nd, Jason Ryan sold 3,154 shares of Foundation Medicine stock. The stock was sold at an average price of $38.80, for a total transaction of $122,375.20.

Foundation Medicine Inc (NASDAQ:FMI) traded down $0.60 during midday trading on Thursday, hitting $58.30. 306,400 shares of the company traded hands, compared to its average volume of 232,342. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a twelve month low of $17.10 and a twelve month high of $70.75.

Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The business had revenue of $42.66 million for the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The firm’s revenue for the quarter was up 45.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.90) EPS. equities analysts expect that Foundation Medicine Inc will post -4.44 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Fiduciary Trust Co. acquired a new stake in Foundation Medicine in the second quarter valued at approximately $119,000. Legal & General Group Plc boosted its position in Foundation Medicine by 8.6% in the second quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock valued at $138,000 after buying an additional 274 shares in the last quarter. Bank of America Corp DE boosted its position in Foundation Medicine by 65.8% in the first quarter. Bank of America Corp DE now owns 6,180 shares of the company’s stock valued at $200,000 after buying an additional 2,452 shares in the last quarter. SG Americas Securities LLC boosted its position in Foundation Medicine by 36.6% in the third quarter. SG Americas Securities LLC now owns 6,481 shares of the company’s stock valued at $261,000 after buying an additional 1,736 shares in the last quarter. Finally, Voya Investment Management LLC acquired a new stake in Foundation Medicine in the second quarter valued at approximately $262,000. Hedge funds and other institutional investors own 33.44% of the company’s stock.

Several analysts recently issued reports on FMI shares. Zacks Investment Research upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Monday, November 6th. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Foundation Medicine currently has an average rating of “Buy” and an average target price of $45.33.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-21726-shares.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.